HIV drug switch may protect hearts: small study hints at benefit
NCT ID NCT04820933
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 35 times
Summary
This early-phase study tested whether switching HIV medications to doravirine (with emtricitabine/tenofovir alafenamide) could improve cholesterol and reduce early signs of heart disease in 26 people with well-controlled HIV. Participants had stable HIV and high cholesterol. The study measured how the change affected HDL function and other markers of artery health. Results may guide safer long-term HIV treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK FACTOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Southwestern
Dallas, Texas, 75219, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75219, United States
Conditions
Explore the condition pages connected to this study.